Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

The MOU marks a significant step in strengthening the Kingdom’s healthcare sector and pharmaceutical manufacturing ...

Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% ...

Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or ...

FDA Commissioner Marty Makary talks about his plans to revamp drug development and reduce ‘conflicts of interest’ between the ...

Ayna joins Antag with extensive experience in obesity and clinical pharmacology. She most recently served as Senior Principal ...

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Beleaguered Belgian biotech Galapagos said yesterday that its CEO, Paul Stoffels, plans to retire upon the appointment of his ...

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...